Heart Failure
Conditions
Keywords
HF, HFrEF, HFpEF, MRI, biomarker
Brief summary
To build on Singapore's competitive advantages in advanced cardiac imaging, genetic and molecular studies to develop an integrated one -stop platform spanning from human to large and small animal models, dedicated to deepening the understanding of CV disease progression, discovery of new targets and repurposing of drugs.
Detailed description
Heart failure (HF) is the final common pathway of cardiovascular (CV) diseases and leading cause of CV hospitalizations in Singapore and worldwide, with a mortality rate that rivals most cancers (\>50% mortality at 5 years). Also similar to cancer, HF is a staged disease where early detection and treatment are vital for prevention of disease progression from Stage A (risk factors) to Stage B (subclinical structural heart disease) and Stage C (symptomatic HF). Cardiac imaging is critical for the detection of early subclinical disease. There is limited understanding of the mechanisms underlying disease progression and effective therapies are limited, particularly for the half of the HF population with preserved ejection fraction (HFPEF or diastolic HF) for which there is no effective therapy to date (in contrast to HF with reduced ejection fraction \[HFREF\] or systolic HF). The investigators overall aim is to build on Singapore's competitive advantages in advanced cardiac imaging, genetic and molecular studies to develop an integrated one -stop platform spanning from human to large and small animal models, dedicated to deepening the understanding of CV disease progression, discovery of new targets and repurposing of drugs.
Interventions
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
OTHERBlood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
OTHERClinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
OTHERCardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
OTHERCognitive Test
To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
Sponsors
Singapore General Hospital
National University Hospital, Singapore
Tan Tock Seng Hospital
Khoo Teck Puat Hospital
Changi General Hospital
National Heart Centre Singapore
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 21-99 2. Present to hospital with diagnosis of HF, or Attending a hospital clinic for management of HF within 6/12 of an episode of decompensated heart failure\* which either: * Resulted in a hospital admission (primary diagnosis) or * Was treated in out-patient clinic \* Appropriate symptoms and signs of HF, confirmed by PI when necessary
Exclusion criteria
1. HF primary due to severe valve disease 2. The primary diagnosis is an Acute coronary syndrome (ACS) which has resulted in a transient episode of Acute pulmonary oedema (APO) (Note: Patients with a troponin rise noted during the index admission, but in whom the main presentation is considered clinically to the HF will be included) 3. End stage renal failure (eGFR \< 15ml/min/m2) or is receiving or planned to receive renal replacement therapy. 4. Other specific subgroups of HF (Including constrictive pericarditis, complex adult congenital heart disease, hypertrophic cardiomyopathy, eosinophilic myocarditis, cardiac amyloid and acute chemotherapy-induces cardiomyopathy) 5. Isolated right heart failure\*\* (combined right and left heart failure will be included). (Secondary to severe lung disease or pulmonary hypertension) 6. Life threatening co-morbidity with a life expectancy of \< 1 year 7. Inability to provide informed consent 8. The patient is unable to comply with study protocol requirements 9. The patient is participating in another clinical research trial(only if that study precludes involvement in an observational study) 10. The patient has declined to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First occurrence of cardiovascular event. | 3 Year |
Countries
Singapore
Outcome results
None listed